Form 8-K - Current report:
SEC Accession No. 0001193125-25-268134
Filing Date
2025-11-06
Accepted
2025-11-06 08:03:38
Documents
12
Period of Report
2025-11-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K whwk-20251106.htm   iXBRL 8-K 51464
2 EX-99.1 whwk-ex99_1.htm EX-99.1 275638
3 GRAPHIC img130881248_0.jpg GRAPHIC 131794
  Complete submission text file 0001193125-25-268134.txt   627074

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT whwk-20251106.xsd EX-101.SCH 24877
14 EXTRACTED XBRL INSTANCE DOCUMENT whwk-20251106_htm.xml XML 4735
Mailing Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960
Business Address 2 HEADQUARTERS PLAZA EAST BUILDING, 11TH FLOOR MORRISTOWN NJ 07960 551-321-2234
Whitehawk Therapeutics, Inc. (Filer) CIK: 0001422142 (see all company filings)

EIN.: 611547850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38560 | Film No.: 251456266
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)